Beijing Hotgen Biotech Co., Ltd.

Equities

688068

CNE100003P82

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 16/05/2024 am IST			5-day change	1st Jan Change
29.55 ^CNY	0.00%		-8.66%	-28.01%

29/04	Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/04	Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan	MT

Hangzhou Oriomics Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd., Tao Capital, Beijing Hotgen Biotech Co., Ltd. and other investors

September 11, 2023

Hangzhou Oriomics Biotechnology Co., Ltd. announced that it has raised nearly CNY 100 million in a round of funding led by new investor, Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd. on September 11, 2023. The transaction also included participation from new investors, Tao Capital, Beijing Hotgen Biotech Co., Ltd. and company's management team.

Latest news about Beijing Hotgen Biotech Co., Ltd.

Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan	16/04	MT
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.	03/04	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	08/02	CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan.	07/02	CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) dropped from S&P Global BMI Index	18/12	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) added to S&P Global BMI Index	18/23/18	CI
Hangzhou Oriomics Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd., Tao Capital, Beijing Hotgen Biotech Co., Ltd. and other investors	11/23/11	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	16/23/16	CI
Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on September 6, 2022 has closed with 2,861,477 shares, representing 3.12% for CNY 166.45 million.	13/23/13	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	07/23/07	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	05/23/05	CI
Beijing Hotgen Biotech Unit Secures Registration Certificate For Two Devices	22/22/22	MT
Beijing Hotgen Biotech Gets Registration Certificate for Hepatitis B Assay Kit; Shares Fall 4%	16/22/16	MT
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/22/24	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	12/22/12	CI
Beijing Hotgen Biotech’s Board Approves Up to $43 Million Share Buyback	07/22/07	MT
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.	06/22/06	CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan.	06/22/06	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI

Chart Beijing Hotgen Biotech Co., Ltd.

Duration

Period

More charts

Company Profile

Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BEIJING HOTGEN BIOTECH CO., LTD.	-28.01%	366M
ABBOTT LABORATORIES	-4.72%	182B
MEDTRONIC PLC	+3.96%	112B
BECTON, DICKINSON AND COMPANY	-2.93%	68.58B
DEXCOM, INC.	+6.30%	51.58B
CENCORA, INC.	+8.02%	44.24B
HOYA CORPORATION	+9.45%	43.65B
METTLER-TOLEDO INTERNATIONAL, INC.	+26.18%	32.46B
TERUMO CORPORATION	+20.94%	25.99B
WEST PHARMACEUTICAL SERVICES, INC.	+0.57%	25.61B

Other Medical Equipment, Supplies & Distribution